SI-BONE, Inc. (SIBN): Results of Operations and Financial Condition
SI-BONE, Inc. (SIBN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance Delivered ~15% WW revenue growth and ~178% increase in adjusted EBITDA ~19% increase in U.S. physician base Second Quarter 2026 Financial Highlights (all comparisons are to t
How this was made
The 30-second read
Why it matters
The key tradable items are the raised FY2026 revenue range ($231M-$233M) and updated operating expense growth rate (~12% vs ~12.5% prior), supported by improved Q2 adjusted EBITDA and cash from operations.
Market read
Traders can reprice SI-BONE’s FY2026 growth and profitability trajectory based on the guidance raise and quantified Q2 improvements, with additional attention on reimbursement timing and the planned Q4 breakthrough device launch.
What to watch
Investors may discount the guidance if procedure volume growth slows, if reimbursement changes do not translate into utilization quickly, or if new product rollout costs pressure margins beyond the stated ~79% gross margin.
Background
This is SI-BONE’s SEC Form 8-K (Item 2.02) with Q2 2026 results and an August 3, 2026 update to FY2026 financial guidance.
Ticker impact
SI-BONE reported Q2 2026 revenue of $56.0M, adjusted EBITDA of $2.8M, and raised FY2026 revenue guidance to $231M-$233M.
Likely positive bias for the next few sessions as traders reprice FY2026 growth and margin/expense trajectory; follow-through depends on execution of the Q4 breakthrough device and CMS reimbursement effective Oct 1.
The filing is a primary disclosure (8-K with earnings exhibit) and includes specific, updated FY2026 revenue and operating expense guidance, alongside quantified Q2 operating and cash metrics.
Market effects
Reimbursement update (CMS MS-DRG family effective Oct 1) can improve demand visibility for spine fusion technologies, supporting sentiment toward procedural device makers.
Primarily US-focused read-through given the company’s US revenue growth and physician base expansion.
International growth cited from iFuse TORQ products may modestly support broader medtech procedural adoption narratives, but the guidance is mainly US-led.
Counterpoint
Despite guidance raise, the company still reports net losses and operating expenses are rising, so the market may scrutinize sustainability of profitability and cash generation.
Key entities
- public_companySI-BONE, Inc.
Reported Q2 2026 financial results and raised FY2026 guidance; highlighted physician base growth, product pipeline, and CMS reimbursement changes.
- regulatorCMS (Centers for Medicare & Medicaid Services)
Finalized MS-DRG family with higher payments for complex spinal fusion procedures using iFuse Bedrock Granite, effective Oct 1.
